Literature DB >> 29529667

Late Reinfection May Recur More Than 5 Years After Reimplantation of THA and TKA: Analysis of Pathogen Factors.

Kevin L Garvin1, Ryan E Miller, Todd M Gilbert, Anthony M White, Elizabeth R Lyden.   

Abstract

BACKGROUND: Two-stage reimplantation has consistently yielded high rates of success for patients with chronic prosthetic joint infection, although results more than 5 years after reimplantation are not commonly reported. Numerous factors may contribute to the risk of reinfection, although these factors-as well as the at-risk period after reimplantation-are not well characterized. QUESTIONS/PURPOSES: (1) What is the risk of reinfection after reimplantation for prosthetic joint infection at a minimum of 5 years? (2) Is the bacteriology of the index infection associated with late reinfection? (3) Is the presence of bacteria at the time of reimplantation associated with late reinfection?
METHODS: Between 1995 and 2010, we performed 97 two-stage revisions in 93 patients for prosthetic joint infection of the hip or knee, and all are included in this retrospective study. During that time, the indications for this procedure generally were (1) infections occurring more than 3 months after the index arthroplasty; and (2) more acute infections associated with prosthetic loosening or resistant organisms. One patient (1%) was lost to followup; all others have a minimum of 5 years of followup (mean, 11 years; range, 5-20 years) and all living patients have been seen within the last 2 years. Patients were considered free from infection if they did not have pain at rest or constitutional symptoms such as fever, chills, or malaise. The patients' bacteriology and resistance patterns of these organisms were observed with respect to recurrence of infection. Odds ratios and Fisher's exact test were performed to analyze the data. The incidence of reinfection was determined using cumulative incidence methods that considered death as a competing event.
RESULTS: Reinfection occurred in 12 of the 97 joints resulting in implant revision. The estimated 10-year cumulative incidence of infection was 14% (95% confidence interval [CI], 7%-23%) and incidence of infection from the same organism was 5% (95% CI, 1%-11%). Five occurred early or within 2 years and three were resistant pathogens (methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis, or vancomycin-resistant Enterococcus). Seven late hematogenous infections occurred and all were > 4 years after reimplantation and involved nonresistant organisms. Three of the five (60%) early infections were caused by resistant bacteria, whereas all seven late infections were caused by different organisms or a combination of different organisms than were isolated in the original infection. The early reinfections were more often caused by resistant organisms, whereas late infections involved different organisms than were isolated in the original infection and none involved resistant organisms. With the numbers available, we found no difference between patients in whom bacteria were detected at the time of reimplantation and those in whom cultures were negative in terms of the risk of reinfection 5 years after reimplantation (18.6% [18 of 97] versus 81.4% [79 of 97], odds ratio 1.56 [95% CI, 0.38-6.44]; p = 0.54); however, with only 93 patients, we may have been underpowered to make this analysis.
CONCLUSIONS: In our study, resistant organisms were more often associated with early reinfection, whereas late failures were more commonly associated with new pathogens. We believe the most important finding in our study is that substantial risk of late infection remains even among patients who seemed free from infection 2 years after reimplantation for prosthetic joint infections of the hip or knee. This highlights the importance of educating our patients about the ongoing risk of prosthetic joint infection. LEVEL OF EVIDENCE: Level III, therapeutic study.

Entities:  

Mesh:

Year:  2018        PMID: 29529667      PMCID: PMC6259703          DOI: 10.1007/s11999.0000000000000050

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  39 in total

1.  Two-stage reimplantation for periprosthetic knee infection involving resistant organisms.

Authors:  Yogesh Mittal; Thomas K Fehring; Arlen Hanssen; Camelia Marculescu; Susan M Odum; Douglas Osmon
Journal:  J Bone Joint Surg Am       Date:  2007-06       Impact factor: 5.284

2.  Two-stage revision arthroplasty of the hip for infection using an interim articulated Prostalac hip spacer: a 10- to 15-year follow-up study.

Authors:  G S Biring; T Kostamo; D S Garbuz; B A Masri; C P Duncan
Journal:  J Bone Joint Surg Br       Date:  2009-11

3.  Articulated spacer provides long-term knee improvement after two-stage reimplantation.

Authors:  Michele Vasso; Chiara Del Regno; Katia Corona; Rocco D'Apolito; Alfredo Schiavone Panni
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2016-07-11       Impact factor: 4.342

4.  Cementless two-staged total hip arthroplasty for deep periprosthetic infection.

Authors:  Matthew J Kraay; Victor M Goldberg; Steven J Fitzgerald; Michael J Salata
Journal:  Clin Orthop Relat Res       Date:  2005-12       Impact factor: 4.176

5.  Modern treatment of infected total knee arthroplasty with a 2-stage reimplantation protocol.

Authors:  Geoffrey H Westrich; Sarah Walcott-Sapp; Lindsey J Bornstein; Mathias P Bostrom; Russell E Windsor; Barry D Brause
Journal:  J Arthroplasty       Date:  2010-10       Impact factor: 4.757

6.  Two-stage reimplantation of total joint infections: a comparison of resistant and non-resistant organisms.

Authors:  Steven J Volin; Steven H Hinrichs; Kevin L Garvin
Journal:  Clin Orthop Relat Res       Date:  2004-10       Impact factor: 4.176

7.  Ten-year experience using an articulating antibiotic cement hip spacer for the treatment of chronically infected total hip.

Authors:  Aaron A Hofmann; Tyler D Goldberg; Amie M Tanner; Thomas M Cook
Journal:  J Arthroplasty       Date:  2005-10       Impact factor: 4.757

8.  Results after late polymicrobial, gram-negative, and methicillin-resistant infections in knee arthroplasty.

Authors:  José Cordero-Ampuero; Jaime Esteban; Eduardo García-Rey
Journal:  Clin Orthop Relat Res       Date:  2010-05       Impact factor: 4.176

9.  Two-stage reimplantation for the salvage of infected total knee arthroplasty.

Authors:  J N Insall; F M Thompson; B D Brause
Journal:  J Bone Joint Surg Am       Date:  1983-10       Impact factor: 5.284

10.  Oral antibiotics are effective for highly resistant hip arthroplasty infections.

Authors:  José Cordero-Ampuero; Jaime Esteban; Eduardo García-Cimbrelo
Journal:  Clin Orthop Relat Res       Date:  2009-03-31       Impact factor: 4.176

View more
  5 in total

Review 1.  Re-examining causes of surgical site infections following elective surgery in the era of asepsis.

Authors:  John C Alverdy; Neil Hyman; Jack Gilbert
Journal:  Lancet Infect Dis       Date:  2020-01-29       Impact factor: 25.071

2.  CORR Insights®: Late Reinfection May Recur More Than 5 Years After Reimplantation of THA and TKA: Analysis of Pathogen Factors.

Authors:  José Cordero-Ampuero
Journal:  Clin Orthop Relat Res       Date:  2018-02       Impact factor: 4.176

3.  Two-stage revision surgery for periprosthetic joint infection following total hip arthroplasty.

Authors:  Timothy J Fowler; Adrian Sayers; Michael R Whitehouse
Journal:  Ann Transl Med       Date:  2019-12

4.  Retrospective Study from a Single Center to Identify Risk Factors Associated with Reinfection in Patients Undergoing 2-Stage Revision Surgery for Periprosthetic Joint Infection.

Authors:  Bingshi Zhang; Zeming Liu; Sikai Liu; Bo Liu; Mengnan Li; Wenao Li; Yongtai Han
Journal:  Med Sci Monit       Date:  2022-06-13

5.  Nasal decolonization of Staphylococcus aureus and the risk of surgical site infection after surgery: a meta-analysis.

Authors:  Jia Tang; Jiangjin Hui; Jing Ma; Chen Mingquan
Journal:  Ann Clin Microbiol Antimicrob       Date:  2020-07-30       Impact factor: 3.944

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.